Company intelligence / Profile preview

Freeline Therapeutics

Stevenage, United Kingdomfreeline.life ↗

Ownership: Public · FRLN
Employees: ~57
Development stage: Phase 2

Overview

Freeline has advanced multiple AAV-based gene therapies into Phase 1/2 trials. FLT180a for hemophilia B has shown promising results in early studies. FLT190 for Fabry disease and FLT201 for Gaucher disease type 1 are also in Phase 1/2 trials. The company aims to provide one-time curative treatments by delivering functional copies of therapeutic genes to the liver using its proprietary platform.

Therapeutic areas: HematologyRare Diseases
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

3 assets

SBT-101

Preclinical

2 more assets in the full pipeline.

Request access →

Financials

Market cap: $28.3M
Total revenue: $5K
Enterprise value: $2.8M

Beyond the preview

Go deeper on Freeline Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Freeline Therapeutics.

Explore the full profile